25 maj: TD A/S - sletning
27 maj: Allergivaccinationstablet til behandling af træpollenallergi: Nye..
27-05-2018 08:15:00

Allergy experts: "Clinical effect of ALK’s tree SLIT-tablet among the most significant ever seen in allergy immunotherapy trials"

Relateret indhold
14 sep - 
ALK-Abelló/Kempen: Reducerer til "sælg" og fastholder k..
14 sep - 
ALK-Abelló: Amerikanere reducerer sats på kursfald
13 sep - 
Torsdagens aktier: Japansk udfald mod Ambu trak aktien ..
Relateret debat
22 aug - 
Der hvor jeg tror man undervurderer potentialet er hast..
22 aug - 
Den har ihvertfald lavet et GC d. 08.06.2018, og b&arin..
22 aug - 
Alk brager nu igennem 1200. Men hvor langt skal den op ..

  • Leading allergy researchers present Phase III data on tree SLIT-tablet at EAACI Annual Congress in Munich

  • Birch pollen-based product shown to be effective against multiple tree allergies

  • Effect shown to be comparable across the entire birch, alder and hazel pollen season.

ALK today announced that leading allergy researchers at a company-sponsored symposium have been the first to be presented with the full clinical and immunological data from a recent Phase III clinical trial of its new investigational tree sublingual allergy immunotherapy (SLIT) tablet.

The symposium took place in Munich, Germany, as part of the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI), at which clinical experts outlined the societal impact of tree pollen allergies and the potential benefits of treating patients with the tree SLIT-tablet.

Clinical endpoint achieved

The trial was initiated by ALK in 2016 to evaluate the efficacy and safety of ALK’s tree SLIT-tablet compared with placebo in adult and adolescent patients with birch pollen allergic rhinitis and/or conjunctivitis, and was a randomised, placebo-controlled, double-blind, multi-centre trial involving 634 patients aged 12-65 years in eight European countries.

The initial topline analysisi showed that the trial met its primary endpoint for the daily total combined score (TCS) – the sum of the allergy symptom score and the use of symptom-relieving medication – during the birch pollen season. The tree SLIT-tablet reduced the TCS by 39.6% versus placebo, which was highly statistically significant (p < 0.0001).="" the="" effect="" was="" shown="" to="" be="" comparable="" across="" the="" entire="" birch,="" alder="" and="" hazel="" pollen="" season,="" spanning="" from="" early="" january="" to="" end="" june="" across="">

Explorative end-of-trial oral apple challenge in a sub-group of the trial population demonstrated that treatment with the tree SLIT-tablet also have a positive impact on pollen food syndrome – a condition experienced by the majority of patients with birch allergy, and caused by a cross-reacting allergic response to structurally related food proteins, especially in fruit and nuts.

Multiple tree pollen, one treatment

In his presentation ‘Confirming efficacy beyond birch: results from the European Phase III field trial’, Professor and principal investigator Tilo Biedermann of the Technical University of Munich said: “The clinical effect seen in this trial is among the most significant seen in allergy immunotherapy field studies. It is particularly noteworthy that birch pollen allergen, when refined into the active pharmaceutical ingredient used here, is effective in treatment of symptoms caused by closely related tree pollen and induces specific antibody responses towards these.”

Allergic rhinitis (with or without conjunctivitis) represents a global health problem affecting 10 to 25% of the population. The prevalence in the general population in Europe and North America is ~20%. In Northern and Central Europe, USA and Canada, respiratory allergies are commonly caused by allergens from pollen of the birch homologous group of trees, which also includes alder, beech, hazel and oak.ii 10-20% of people with allergic rhinitis have a condition which is not well controlled. For some of these people with uncontrolled allergies to tree pollen, ALK’s tablet may become a relevant treatment option. Tree pollen is considered one of the five most significant respiratory allergen sources and with its core European season usually lasting from at least January to June.

Proven tablet technology

Henrik Jacobi, ALK’s Executive Vice President of Research and Development, said: “The tree tablet will extend the range of ALK registered SLIT-tablets which already includes grass, house dust mite and ragweed in Europe and North America. It leverages the same well-proven technology that has shown consistent clinical results across a development program of more than 20.000 patients. The addition of the tree tablet will allow the ALK SLIT-tablet range to cover all of the world's most important respiratory allergic diseases.”

A regulatory filing for the tree SLIT-tablet in Europe is planned for 2018.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,300 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net

.

About the EAACI Congress

EAACI is Europe’s largest medical association for allergy and clinical immunology. Its annual congress draws allergy experts, healthcare policy makers and science media from all over the world to network, share knowledge, and hear about the latest discoveries. The 2018 EAACI Congress is being held from 26-30 May in Munich, Germany.


i See company release: Successful Phase III trial for ALK’s tree allergy SLIT-tablet (2017-09-14) https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=791334&lang=en

ii Birch homologous group includes: Betula verrucosa (European white birch), Alnus glutinosa (alder), Corylus avellana (hazel), Carpinus betulus (hornbeam), Quercus alba (white oak), Castanea satavia (sweet chestnut), Fagus sylvatica (common beech). Reference: Lorenz AR et al. Int Arch Allergy Immunol. 2009;148(1):1–17.

Attachment

Primary Logo

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Coloplast/dir: Skift i ambitionsniveauet er afgørende for væksten

18-09-2018 15:10:18
Den danske medicokoncern Coloplast har taget de første skridt i strategien om at få højere priser for klinisk dokumenterede produkter, og det kommer til at spille en afgørende rolle for selskabets vækst i fremtiden.- Det er ekstremt vigtigt. Vi opfatter det her skifte i ambitionsniveauet som afgørende for, at vi kan forøge vækstmomentum, siger Kristian Villumsen, der er direktør for den kroniske f..

Mærsk/analytikere: Frasalg trak lidt ud men er nu så godt som i mål

18-09-2018 13:45:01
Når A.P. Møller-Mærsk næste år er klar til at sende Maersk Drilling, som ejer rigge og skibe, der borer efter olie og gas til havs på vegne af olieselskaberne, på børsen som et selvstændigt selskab, er koncernen også så godt som i mål med den ene del af strategien, som blev lanceret i 2016.På lørdag er det præcis to år siden, at Mærsk løftede sløret for en ny strategi, der skulle være med til at t..

Mærsk/analytikere: Strategiske ændringer skal samle selskabet i ét

18-09-2018 11:15:00
Mærsk-koncernen rammer i denne uge toårsdagen for lanceringen af den nye strategi, hvor selskabet blev samlet i to enheder - en for transport- og logistikaktiviteter og en for energiaktiviteter.Og mens planerne for energiaktiviteterne, der efter planen skal udskilles helt, er ved at være fuldbragte, resterer der fortsat en del arbejde med transport- og logistikforretningen, hvor flagskibet stadig ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Spændingen stiger omkring Danske Bank
2
Pandora: Stiger på rygter i markedet om muligt bud - NY
3
Aktier/middag: Pandora banket op af italienske rygter
4
Novo Nordisk reorganiserer R&D - 400 medarbejdere afskediges - NY
5
Pandora/Sydbank: Lav værdisætning kan udnyttes af kapitalfonde

Relaterede aktiekurser

ALK-Abelló B A/S 1.120,00 -0,4% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. september 2018 05:04:49
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180917.3 - EUROWEB3 - 2018-09-19 05:04:49 - 2018-09-19 05:04:49 - 1 - Website: OKAY